Literature DB >> 9389231

Usefulness of antinuclear antibody testing to screen for rheumatic diseases.

P N Malleson1, M Sailer, M J Mackinnon.   

Abstract

OBJECTIVE: To assess the usefulness of the indirect immunofluorescence antinuclear antibody test (FANA) using human laryngeal epithelial carcinoma cells as nuclear substrate, to screen for childhood rheumatic diseases. STUDY
DESIGN: A review of all FANA tests performed on children at British Columbia's Children's Hospital between 7 March 1991 and 31 July 1995.
RESULTS: FANA tests were positive at titres of 1:20 or greater in 41% of all subjects tested, and in 65% of all subjects in whom the diagnosis was obtained. FANA positivity occurred in 67% of those with a rheumatic disease, compared with 64% of those with a non-rheumatic disease (p = 0.4). More girls had high titre FANA positivity than boys independent of whether or not they had a rheumatic disease (p = 0.05). At a screening serum dilution of 1:40 a positive test has a sensitivity of only 0.63, and a positive predictive value of only 0.33 for any rheumatic disease. For systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), or overlap syndrome at a screening dilution of 1:40 the test has a very high sensitivity of 0.98, but a very low positive predictive value of only 0.10, the test having slightly better characteristics for boys than girls.
CONCLUSION: Although a negative FANA test makes a diagnosis of SLE or MCTD extremely unlikely, a positive test even at moderately high titres of 1:160 or higher is found so frequently in children without a rheumatic disease that a positive result has little or no diagnostic value. It is suggested that a screening serum dilution of 1:160 or 1:320 would increase the usefulness of the test, by decreasing false positive tests, without significantly increasing false negative tests for SLE or MCTD, and would have the potential for considerable cost savings.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389231      PMCID: PMC1717342          DOI: 10.1136/adc.77.4.299

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  9 in total

1.  The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry.

Authors:  P N Malleson; M Y Fung; A M Rosenberg
Journal:  J Rheumatol       Date:  1996-11       Impact factor: 4.666

2.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

3.  The frequency of antinuclear antibody (ANA) in children by use of mouse kidney (MK) and human epithelial cells (HEp-2) as substrates.

Authors:  C M Arroyave; M J Giambrone; K C Rich; M Walaszek
Journal:  J Allergy Clin Immunol       Date:  1988-11       Impact factor: 10.793

4.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

5.  Autoantibodies in juvenile dermatomyositis.

Authors:  C Montecucco; A Ravelli; R Caporali; S Viola; F De Gennaro; S Albani; A Martini
Journal:  Clin Exp Rheumatol       Date:  1990 Mar-Apr       Impact factor: 4.473

6.  The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease.

Authors:  P M Deane; G Liard; D M Siegel; J Baum
Journal:  Pediatrics       Date:  1995-06       Impact factor: 7.124

7.  Autoantibody profiles in juvenile arthritis.

Authors:  D C Haynes; M E Gershwin; D L Robbins; J J Miller; D Cosca
Journal:  J Rheumatol       Date:  1986-04       Impact factor: 4.666

8.  Significance of a positive antinuclear antibody test in a pediatric population.

Authors:  D S Chudwin; A J Ammann; M J Cowan; D W Wara
Journal:  Am J Dis Child       Date:  1983-11

9.  Persistent antinuclear antibodies in children without identifiable inflammatory rheumatic or autoimmune disease.

Authors:  D A Cabral; R E Petty; M Fung; P N Malleson
Journal:  Pediatrics       Date:  1992-03       Impact factor: 7.124

  9 in total
  21 in total

1.  Aspergillus antigen testing in bone marrow transplant recipients.

Authors:  E C Williamson; D A Oliver; E M Johnson; A B Foot; D I Marks; D W Warnock
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

2.  Rheumatology: 16. Diagnosing musculoskeletal pain in children.

Authors:  P N Malleson; R D Beauchamp
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

3.  An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy.

Authors:  Aysun Caltik; Gülay Demircin; Mehmet Bülbül; Ozlem Erdogan; Sare G Akyüz; Nilüfer Arda
Journal:  Rheumatol Int       Date:  2010-06-08       Impact factor: 2.631

4.  Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies.

Authors:  Insoo Kang; Robyn Siperstein; Tim Quan; Mary Lou Breitenstein
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

Review 5.  Laboratory tests in pediatric rheumatology.

Authors:  Manjari Agarwal; Sujata Sawhney
Journal:  Indian J Pediatr       Date:  2010-08-26       Impact factor: 1.967

6.  Comparative study of immunofluorescent antinuclear antibody test and line immunoassay detecting 15 specific autoantibodies in patients with systemic rheumatic disease.

Authors:  Sun Ah Lee; Jimin Kahng; Yonggoo Kim; Yeon-Joon Park; Kyungja Han; Seung-Ki Kwok; Sung-Hwan Park; Eun-Jee Oh
Journal:  J Clin Lab Anal       Date:  2012-07       Impact factor: 2.352

7.  Testing for Rheumatological Diagnoses in Children.

Authors:  Judith A Smith
Journal:  Eur Paediatr Rev       Date:  2009

8.  Characteristics of children with acute lymphoblastic leukemia presenting with arthropathy.

Authors:  Ninna Brix; Henrik Hasle; Steen Rosthøj; Troels Herlin
Journal:  Clin Rheumatol       Date:  2018-02-21       Impact factor: 2.980

9.  Juvenile idiopathic arthritis-associated uveitis: Data from a region in western Greece.

Authors:  Ioannis Asproudis; Taxiarchis Felekis; Elena Tsanou; Spiridon Gorezis; Eikaterini Karali; Sapfo Alfantaki; Antigoni Siamopoulou-Mauridou; Miltiadis Aspiotis
Journal:  Clin Ophthalmol       Date:  2010-04-26

Review 10.  Use of biomarkers in the management of children with lupus.

Authors:  Elisabeth Binder; Monika Edelbauer
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.